Aletra Capital Partners

What is Aletra Capital Partners?

Aletra Capital Partners is a venture capital firm specializing in investments across B2B enterprise, software, and medtech sectors.

They focus on companies with initial revenue and product-market fit, indicated by an annual recurring revenue of over USD 1 million and the potential for global scaling. They are a hands-on investment company, actively involved in corporate divestitures of non-core business units, family-owned businesses needing succession solutions, and stand-alone companies that require turnaround management or growth acceleration. In Singapore, their attention turns to young ventures seeking bridge or pre-series financing.

Aletra Capital Partners works intimately with management teams to foster growth and enhance value, supporting activities ranging from restructuring to initiating growth programs. They fund equity stakes with their own funds, steering clear of leveraging other people's money and avoiding covenants of external institutions, granting them the flexibility to invest in opportunities they genuinely believe in and to where they can contribute significant value.

The firm is committed to long-term investments, opposing quick buy-and-flip strategies that might harm companies for short-term investor gains. They invest in companies operating in medical technology or IT/software, specifically in medical devices, assays, biomarkers, reagents, medical embedded IT, and general IT/software.

They seek businesses with international potential, an understandable and scalable business model, and openness to a new majority shareholder. Their investment focus is primarily on companies headquartered in the Netherlands, Belgium, or Germany.

With an investment range between EUR 250,000 and EUR 2,500,000, they can commit equity stakes between EUR 1 million and EUR 5 million. For investments that surpass their threshold, they are willing to collaborate with other private equity firms.

What they say:

We invest in B2B enterprise/software/medtech companies. The venture should have initial revenue/product market fit (ARR> USD 1Mln) and the potential to scale globally.